Nov, 05, 2018

Soleo Health Chosen to Distribute Specialty Drug by Shire

Company Continues to Gain Access to Specialty Drugs Based on its Clinical Excellence and Proven Track Record

McKINNEY, Texas, November 5, 2018 – Soleo Health, an innovative leader in specialty infusion services, announced today it has been chosen by Shire, the leading global biotechnology company focused on rare diseases, as a provider of the specialty drug VONVENDI®. [von Willebrand factor (Recombinant)].

VONVENDI is the first and only recombinant von Willebrand factor (rVWF or VWF), designed specifically for treating and managing adults with von Willebrand disease (VWD). VWD is the most common bleeding disorder today, which occurs when blood does not clot properly. VWD affects up to one percent of the world’s population[1], and many people are not accurately diagnosed. VWD is caused by a deficiency or dysfunction of VWF, one of several types of proteins in the blood needed to facilitate proper blood clotting, resulting in impaired blood clotting, and it affects women and men equally.[2] [3] VONVENDI works similarly to the body’s naturally occurring VWF, is administered intravenously to replace missing or dysfunctional VWF, and is indicated to treat and control of bleeding episodes and prevent excessive bleeding before and after surgery. Research shows that as many as 9 out of 10 people with VWD have not been diagnosed.[4]

Soleo Health was selected as a specialty drug distribution provider of VONVENDI based on the Company’s dedicated bleeding disorders program with deep clinical knowledge and broad expertise in treating and clinically managing those with bleeding disorders, including VWD. Soleo Health’s clinical and patient advocacy teams have undergone extensive training and education with respect to the dispensing, clinical management and patient support for those receiving VONVENDI.

“Soleo Health is fast-gaining traction as a provider of specialty drugs, having added three medications to our portfolio in the past few months alone. As a leading specialty infusion services provider with licensure in 50 states, we are quickly becoming a preferred provider based on our proven clinical outcomes, positive patient experience and ability to appropriately manage and care for bleeding disorders and other rare diseases. We were chosen by Shire based on this in-depth experience and look forward to adding VONVENDI to our dedicated VWD program offering and support to the VWD community,” noted Craig Vollmer, executive vice president at Soleo Health.

About Shire and VONVENDI

Shire is the global leader in serving patients with rare diseases. The company strives to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, rare diseases, neuroscience, and internal medicine with growing therapeutic areas. Its diversified capabilities allow it to reach patients in more than 100 countries. Shire addresses unmet medical needs and works tirelessly to improve people’s lives with medicines that have a meaningful impact on patients as well as those who support them on their journey. VONVENDI is registered trademark of Shire.

About Soleo Health

McKinney, Texas-based Soleo Health is an innovative national provider of specialty home and alternate-site infusion services. Its team of experienced clinicians provides exceptional clinical care and support in managing patients with complex or chronic conditions through comprehensive therapy management programs. Soleo’s patients’ clinical needs are met by its compassionate and caring associates who deliver personalized care.

Soleo Health operates 19 locations through the U.S. with pharmacy licensure in 50 states and is accredited by The Joint Commission. For more information, visit or connect with Soleo Health on Facebook, Twitter and LinkedIn.

  1. James PD, Goodeve AC. von Willebrand Disease. Genet Med. 2011;13(5):365-76.
  2. Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008;14(2):171-232.
  3. Leebeek FW, Eikenboom JC. Von Willebrand’s Disease. N Engl J Med. 2016;375(21):2067-2080.
    What is von Willebrand disease (VWD)? World Federation of Hemophilia website. Accessed May 3, 2017.